Browsing NTNU Open by Author "Sørhaug, Sveinung"
Now showing items 1-14 of 14
-
Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune Checkpoint and CD200-CD200R Interactions
Tøndell, Anders; Subbannayya, Yashwanth; Wahl, Sissel Gyrid Freim; Flatberg, Arnar; Sørhaug, Sveinung; Børset, Magne; Haug, Markus (Peer reviewed; Journal article, 2021)Lung cancer is the leading cause of cancer-related death worldwide, accounting for nearly one-fifth of all cancer-related deaths. Immunotherapy with immune checkpoint inhibitors has become one of the most promising approaches ... -
Associations Between Time to Treatment Start and Survival in Patients With Lung Cancer
Stokstad, Trine; Sørhaug, Sveinung; Amundsen, Tore; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2021)Background: Time-to-treatment is defined as a quality indicator for cancer care but is not well documented. We investigated whether meeting Norwegian timeframes of 35/42 days from referral until start of chemotherapy or ... -
Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling
Pettersen, Kristine; Andersen, Sonja Benedikte; Degen, simone; Tadini, Valentina; Grosjean, Joel; Hatakeyama, Shinji; Tesfahun, Almaz Nigatu; Moestue, Siver Andreas; Kim, Jana; Nonstad, Unni; Romundstad, Pål Richard; Skorpen, Frank; Sørhaug, Sveinung; Amundsen, Tore; Grønberg, Bjørn Henning; Strasser, Florian; Stephens, Nathan; Hoem, Dag; Molven, Anders; Kaasa, Stein; Fearon, Kenneth; Jacobi, Carsten; Bjørkøy, Geir (Journal article; Peer reviewed, 2017)The majority of cancer patients with advanced disease experience weight loss, including loss of lean body mass. Severe weight loss is characteristic for cancer cachexia, a condition that significantly impairs functional ... -
Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non–small-cell Lung Cancer
Tøndell, Anders; Wahl, Sissel Gyrid Freim; Sponaas, Anne-Marit; Sørhaug, Sveinung; Børset, Magne; Haug, Markus (Journal article; Peer reviewed, 2019)Lung cancer is the leading cause of cancer death in both sexes worldwide and has a predicted 5-year survival rate of <20%. Immunotherapy targeting immune checkpoints such as the programmed death 1 (PD-1) signaling pathway ... -
Evaluering av PET-CT ved lungekreftutredning - Sammenligning før og etter innføring av PET-CT ved St. Olavs Hospital
Bruteig, Johannes Gihle; Ullern, Andreas (Master thesis, 2016)Bakgrunn: PET-CT er et viktig verktøy i stadieinndelingen av lungekreft. Inntil høsten 2013 ble alle pasienter fra Midt-Norge sendt til Bergen (Haukeland sykehus) eller Oslo (OUS eller Aleris) for denne undersøkelsen. Etter ... -
Kirurgi for lungekreft, 2008-2018 St Olavs Hospital
Svorkdal, Bernt Kristian (Master thesis, 2021)Sammendrag 1.1 Bakgrunn Lungekreft er den nest hyppigste kreftformen i Norge, og fører til det høyeste antallet cancerrelaterte dødsfall i landet. Røyking er den absolutt viktigste risikofaktoren. Behandlingen for pasienter ... -
Measurement of health-related quality of life during chemotherapy -the importance of timing
Kristensen, Are Korsnes; Solheim, Tora Skeidsvoll; Amundsen, Tore; Hjelde, Harald Harris; Kaasa, Stein; Sørhaug, Sveinung; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2017)Background: Side effects of chemotherapy may occur at different time-points in the treatment cycle, and the exact assessment time relative to chemotherapy may affect HRQoL scores. The current study examined the variation ... -
Medical complexity and time to lung cancer treatment - A three-year retrospective chart review
Stokstad, Trine; Sørhaug, Sveinung; Amundsen, Tore; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2017)Background The time from a referral for suspected lung cancer is received at a hospital until treatment start has been defined as a quality indicator. Current Norwegian recommendation is that ≥70% should start surgery or ... -
New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss.
Johns, Neil; Stretch, C; Tan, BH; Solheim, Tora Skeidsvoll; Sørhaug, Sveinung; Stephens, NA; Gioulbasanis, Ioannis; Skipworth, RJ; Deans, DA; Vigano, Antonio A.L.; Ross, JA; Bathe, OF; Tremblay, ML; Kaasa, Stein; Strasser, Florian; Gagnon, B; Baracos, VE; Damaraju, S; Fearon, KC (Peer reviewed; Journal article, 2017)Background Cachexia affects the majority with advanced cancer. Based on current demographic and clinical factors, it is not possible to predict who will develop cachexia or not. Such variation may, in part, be due to ... -
A new removable airway stent
Amundsen, Tore; Sørhaug, Sveinung; Leira, Håkon Olav; Tyvold, Stig Sverre; Langø, Thomas; Hammer, Tommy Arild; Manstad-Hulaas, Frode; Mattsson, Erney (Peer reviewed; Journal article, 2016)Background Malignant airway obstruction is a feared complication and will most probably occur more frequently in the future because of increasing cancer incidence and increased life expectancy in cancer patients. Minimal ... -
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje; Fløtten, Øystein; Helbekkmo, Nina; Hornslien, Kjersti; Madebo, Tesfaye; Fluge, Sverre; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung ... -
Reasons for prolonged time for diagnostic workup for stage I-II lung cancer and estimated effect of applying an optimized pathway for diagnostic procedures
Stokstad, Trine; Sørhaug, Sveinung; Amundsen, Tore; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2019)Background:Minimizing the time until start of cancer treatment is a political goal. In Norway, the target time forlung cancer is 42 days. The aim of this study was to identify reasons for delays and estimate the effect on ... -
The Pulmonary Neuroendocrine System: Physiological, pathological and tumourigenic aspects
Sørhaug, Sveinung (Doktoravhandlinger ved NTNU, 1503-8181; 2007:153, Doctoral thesis, 2007)Nevroendokrine (NE) celler er en benevnelse på spesialiserte celler som finnes diffust utbredt i flere organ i kroppen og som har evnen til å produsere og skille ut hormon-liknende substanser. I lungene oppfattes ansamlinger ... -
Timelines in Lung Cancer Diagnostic Workup
Stokstad, Trine (Doctoral theses at NTNU;2019:241, Doctoral thesis, 2019)Lange ventetider for å starte kreftutredning eller -behandling fører til bekymring og oppfattes som en medisinsk risiko som kan påvirke mulighetene til å få effektiv behandling. Derfor er det innført krav til ventetider i ...